Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens

E. Miller; P. A. Waight; L. A.E. Ashworth; A. Robinson; L. I. Irons

doi:10.1016/0140-6736(91)90735-8

Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens

E. Miller^*, P. A. Waight, L. A.E. Ashworth, A. Robinson, L. I. Irons

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

An acellular pertussis vaccine containing agglutinogens 2 and 3, pertussis toxin, and filamentous haemagglutinin was developed by the Centre for Applied Microbiology and Research in the UK. 188 infants were entered into a randomised blind trial and received either the acellular or a whole-cell vaccine, combined with diphtheria and tetanus toxoids, in a 3, 5, and 8-10 month schedule. Local reactions were similar in the two groups but significantly fewer infants had systemic symptoms after the acellular vaccine. Mean log-antibody titres to the agglutinogen and toxin components were higher with the acellular than with the whole-cell vaccine. Persistence of antibodies one year after the third dose was also better in the acellular group.

Original language	English
Pages (from-to)	70-73
Number of pages	4
Journal	The Lancet
Volume	337
Issue number	8733
DOIs	https://doi.org/10.1016/0140-6736(91)90735-8
Publication status	Published - 12 Jan 1991

Bibliographical note

Funding Information:
We thank Mrs C. Andrews and Mr A. ’rhompson who completed the ELISAs, Dr M. Judd (Director of Public Health North Hertfordshire Health Authority), and the study nurses Mrs M. Heath, Mrs M. Hobbs, Mrs L. Joslin, Mrs T. Till, and Mrs M. Wheal. We also thank Mrs K. Harbert who was responsible for study administration and Dr P. Farrington for his help with the statistical analysis. The acellular vaccine was manufactured by the Production Group at CAMR and the whole-cell vaccine was a gift from Wellcome. The study was funded by the Medical Research Council.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/0140-6736(91)90735-8

Cite this

@article{2a6c2352033e40af8be5ecf14fcf338c,

title = "Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens",

abstract = "An acellular pertussis vaccine containing agglutinogens 2 and 3, pertussis toxin, and filamentous haemagglutinin was developed by the Centre for Applied Microbiology and Research in the UK. 188 infants were entered into a randomised blind trial and received either the acellular or a whole-cell vaccine, combined with diphtheria and tetanus toxoids, in a 3, 5, and 8-10 month schedule. Local reactions were similar in the two groups but significantly fewer infants had systemic symptoms after the acellular vaccine. Mean log-antibody titres to the agglutinogen and toxin components were higher with the acellular than with the whole-cell vaccine. Persistence of antibodies one year after the third dose was also better in the acellular group.",

author = "E. Miller and Waight, {P. A.} and Ashworth, {L. A.E.} and A. Robinson and Irons, {L. I.}",

note = "Funding Information: We thank Mrs C. Andrews and Mr A. {\textquoteright}rhompson who completed the ELISAs, Dr M. Judd (Director of Public Health North Hertfordshire Health Authority), and the study nurses Mrs M. Heath, Mrs M. Hobbs, Mrs L. Joslin, Mrs T. Till, and Mrs M. Wheal. We also thank Mrs K. Harbert who was responsible for study administration and Dr P. Farrington for his help with the statistical analysis. The acellular vaccine was manufactured by the Production Group at CAMR and the whole-cell vaccine was a gift from Wellcome. The study was funded by the Medical Research Council.",

year = "1991",

month = jan,

day = "12",

doi = "10.1016/0140-6736(91)90735-8",

language = "English",

volume = "337",

pages = "70--73",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "8733",

}

TY - JOUR

T1 - Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens

AU - Miller, E.

AU - Waight, P. A.

AU - Ashworth, L. A.E.

AU - Robinson, A.

AU - Irons, L. I.

N1 - Funding Information: We thank Mrs C. Andrews and Mr A. ’rhompson who completed the ELISAs, Dr M. Judd (Director of Public Health North Hertfordshire Health Authority), and the study nurses Mrs M. Heath, Mrs M. Hobbs, Mrs L. Joslin, Mrs T. Till, and Mrs M. Wheal. We also thank Mrs K. Harbert who was responsible for study administration and Dr P. Farrington for his help with the statistical analysis. The acellular vaccine was manufactured by the Production Group at CAMR and the whole-cell vaccine was a gift from Wellcome. The study was funded by the Medical Research Council.

PY - 1991/1/12

Y1 - 1991/1/12

N2 - An acellular pertussis vaccine containing agglutinogens 2 and 3, pertussis toxin, and filamentous haemagglutinin was developed by the Centre for Applied Microbiology and Research in the UK. 188 infants were entered into a randomised blind trial and received either the acellular or a whole-cell vaccine, combined with diphtheria and tetanus toxoids, in a 3, 5, and 8-10 month schedule. Local reactions were similar in the two groups but significantly fewer infants had systemic symptoms after the acellular vaccine. Mean log-antibody titres to the agglutinogen and toxin components were higher with the acellular than with the whole-cell vaccine. Persistence of antibodies one year after the third dose was also better in the acellular group.

AB - An acellular pertussis vaccine containing agglutinogens 2 and 3, pertussis toxin, and filamentous haemagglutinin was developed by the Centre for Applied Microbiology and Research in the UK. 188 infants were entered into a randomised blind trial and received either the acellular or a whole-cell vaccine, combined with diphtheria and tetanus toxoids, in a 3, 5, and 8-10 month schedule. Local reactions were similar in the two groups but significantly fewer infants had systemic symptoms after the acellular vaccine. Mean log-antibody titres to the agglutinogen and toxin components were higher with the acellular than with the whole-cell vaccine. Persistence of antibodies one year after the third dose was also better in the acellular group.

UR - http://www.scopus.com/inward/record.url?scp=0025962566&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(91)90735-8

DO - 10.1016/0140-6736(91)90735-8

M3 - Article

C2 - 1670725

AN - SCOPUS:0025962566

VL - 337

SP - 70

EP - 73

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8733

ER -

Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this